Company / R&D per Share
PharmaCyte Biotech, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.05
FY2025
5-year range
$0.03 / $0.58
FY2021-FY2025
Trend
+81.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share returned to growth in FY2025 after 2 years of decline, reaching $0.05.
Based on SEC 10-K filings.
0.05 in FY2025 with a 5-year CAGR of +165.0%.
Improved from $0.03 to $0.05 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -55.5%
- 5-Year CAGR
- +165.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share increased 81.7% year-over-year.
- Peak r&d per share was recorded in FY2022.
- Lowest r&d per share in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.05 | +81.7% |
| FY2024 | $0.03 | -16.3% |
| FY2023 | $0.03 | -94.2% |
| FY2022 | $0.58 | +109.0% |
| FY2021 | $0.28 | +70984.2% |
| FY2020 | $0.00 | -80.3% |
| FY2019 | $0.00 | +51.0% |
| FY2018 | $0.00 | -27.5% |
| FY2017 | $0.00 | +307.9% |
| FY2016 | $0.00 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026